$Bob's and Jbem's Bitchin' Bios

[tominvb]

MRNS, was it because of this push out to Q1 2016?

• Adult Focal Onset Epileptic Seizures:
Enrollment is ongoing in Marinus's Phase 3 clinical trial evaluating ganaxolone in adults with drug-resistant focal onset epileptic seizures. The multi-national, placebo-controlled study is designed to enroll up to 300 patients. Patients are being randomized to receive either placebo or 1,800 mg/day of ganaxolone for 12 weeks. The primary endpoint of this trial is change in seizure frequency per month compared to baseline. Marinus anticipates releasing top-line data in the first quarter of 2016.